The article provides an overview of recent developments in the healthcare sector, including Novo Nordisk's phase-out of ...

In the world of health, Novo Nordisk stops insulin pen production, Trump's potential health appointments draw attention, and ...

Upon reexamination, the European Medicines Agency has made a U-turn on Eisai and Biogen’s Alzheimer’s disease drug Leqembi. | ...

Gilead Sciences has abandoned a liver disease collaboration with Yuhan. A new study suggests Leqembi's vial design could cost Medicare hundreds of millions of dollars in waste each year.

Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients ...

The pharmaceutical segment saw a 5% increase in revenue. LEQEMBI is gaining traction with over 50,000 vials delivered monthly. Regulatory approvals for LEQEMBI have been granted in multiple ...

The body in July rejected Leqembi, saying the risk of serious brain ... In that group, volunteers started with one 350 ...

According to a study published on Oct. 14 in JAMA Internal Medicine, 5.8% of Leqembi doses are wasted due to the use of single-use vials. This results in an estimated annual loss of around $336 ...

It is also developing an Alzheimer's drug candidate, which could compete with current market lead Leqembi from Biogen (BIIB .

As of January this year, Civica had provided nearly 70 million vials of essential medicines ... of sales growth for Alzheimer's disease drug Leqembi it held earlier this year as uptake remains ...